Gilead buys CymaBay for $ 4.3b to expand its liver portfolio
HQ Team February 13, 2024: Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion, to access its portfolio of drugs for liver and.
Drugs
Medical
Pharma